Bilateral PENG Block for Total Vaginal Hysterectomy (PENG)
Bilateral Ultrasound-Guided Pericapsular Nerve Group (PENG) Block for Postoperative Analgesia After Total Vaginal Hysterectomy Under General Anesthesia: A Prospective Exploratory Pilot Study
This prospective, single-arm pilot study will evaluate the feasibility, safety, and preliminary analgesic outcomes of bilateral pericapsular nerve group (PENG) blocks in adult patients undergoing total vaginal hysterectomy (TVH) under general anesthesia at UI Health. The study will target 25 evaluable subjects, with enrollment of up to 30 subjects to account for withdrawal or incomplete data. Following induction of general anesthesia, subjects will receive ultrasound-guided bilateral PENG blocks using 20 mL of 0.2% ropivacaine per side, in addition to standard perioperative analgesic management. Outcomes will include postoperative pain scores, perioperative analgesic requirements, motor weakness and ambulation, postoperative nausea and vomiting, PACU recovery and discharge, and adverse events. Data from this pilot study will be used to characterize the feasibility and safety of the intervention and to inform the design of a future controlled study.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Prima fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Alexandra Barabanova, MS
- Numero di telefono: 312-355-5733
- Email: barabano@uic.edu
Backup dei contatti dello studio
- Nome: Kantarakorn Unchiti, MD PhD
- Email: Kantarakorn.u@gmail.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 18 years or older
- Scheduled to undergo elective total vaginal hysterectomy under general anesthesia
- Planned postoperative recovery in the PACU
- Able to provide written informed consent
- Able to understand and report postoperative pain using the NRS (0-10)
Exclusion Criteria:
Known allergy or hypersensitivity to the local anesthetic selected for the PENG block or to other amide local anesthetics
2. Infection, cellulitis, open wound, or other active skin or soft-tissue infection at or near the proposed block site
3. Known clinically significant coagulopathy, thrombocytopenia, or anticoagulant or antiplatelet therapy that, according to institutional guidelines or the judgment of the treating anesthesiologist, would increase the risk associated with performance of the PENG block
4. Pre-existing clinically significant lower-extremity neurologic or motor deficit that may increase the risk associated with the block or interfere with postoperative assessment of motor or neurologic adverse events
5. Anatomical abnormality, prior surgery involving the proposed block region, or other condition that, in the judgment of the treating anesthesiologist, would prevent adequate visualization of relevant anatomy or safe performance of the PENG block
6. Any medical condition or clinical circumstance that, in the judgment of the treating anesthesiologist or investigator, would increase the risk associated with bilateral PENG block or administration of the study local anesthetic
7. Planned neuraxial anesthesia or another regional anesthetic technique expected to provide perioperative analgesia and interfere with assessment of the study intervention
8. Receipt or planned receipt of additional local anesthetic that would result in a total local anesthetic dose considered unsafe by the treating anesthesiologist
9. Inability to reliably communicate postoperative pain using the NRS
10. Pregnancy
11. Prisoner status
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: PENG Block
Following induction of general anesthesia and prior to surgical positioning, participants will receive bilateral ultrasound-guided PENG blocks |
After negative aspiration and confirmation of appropriate needle position, 20 mL of 0.2% ropivacaine will be administered on each side, for a total volume of 40 mL and a total ropivacaine dose of 80 mg |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative pain intensity during the PACU stay
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Assessed using the Numeric Rating Scale (NRS, 0-10) at PACU arrival (once awake and able to provide a reliable assessment). |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of participants requiring rescue opioid analgesia during the PACU stay
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
|
Location of postoperative pain
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Self-reported by the participant at each PACU assessment and categorized as deep pelvic/vaginal, perineal/introital, suprapubic, groin/hip, medial thigh, or lower back pain |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Cutaneous sensory block, at each PACU pain-assessment timepoint
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
assessed bilaterally in the femoral, saphenous, obturator, lateral femoral cutaneous, genitofemoral (femoral branch), and ilioinguinal/iliohypogastric territories using a 3-point scale |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Correspondence between the anatomical territories in which sensory block is demonstrated and the anatomical location of reported postoperative pain
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
|
Incidence of postoperative nausea and vomiting during the PACU stay
Lasso di tempo: Any time during PACU stay
|
Any time during PACU stay
|
|
|
Duration of PACU stay
Lasso di tempo: PACU Stay
|
PACU Stay
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Lower-extremity motor weakness following bilateral PENG block, a
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Assessed bilaterally by knee extension (quadriceps, femoral nerve) and hip adduction (adductors, obturator nerve) and graded using the Medical Research Council (MRC) 0-5 scale, referenced to the participant's own preoperative baseline examination |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Persistence of sensory or motor block at PACU discharge
Lasso di tempo: PACU discharge
|
Defined as any territory scored as reduced or absent, or any MRC grade below the participant's preoperative baseline, at the final PACU assessment |
PACU discharge
|
|
Falls or near-falls
Lasso di tempo: The postoperative observation period in PACU
|
The postoperative observation period in PACU
|
|
|
Signs or symptoms of local anesthetic systemic toxicity
Lasso di tempo: Starting from the block time until 30 min after the block
|
Cardiovascular System Symptoms
|
Starting from the block time until 30 min after the block
|
|
New lower-extremity sensory or neurological symptoms following the block
Lasso di tempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Weakness in lower-extremity and numbness |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Stephan Cohn, MD, University of Illinois Chicago
Pubblicazioni e link utili
Pubblicazioni generali
- Ciftci B, Ahiskalioglu A, Altintas HM, Tekin B, Sakul BU, Alici HA. A possible mechanism of motor blockade of high volume pericapsular nerve group (PENG) block: A cadaveric study. J Clin Anesth. 2021 Nov;74:110407. doi: 10.1016/j.jclinane.2021.110407. Epub 2021 Jun 24. No abstract available.
- Pai P, Amor D, Lai YH, Echevarria GC. Use and Clinical Relevancy of Pericapsular Nerve Block (PENG) in Total Hip Arthroplasty: A Systematic Review and Meta-analysis. Clin J Pain. 2024 May 1;40(5):320-332. doi: 10.1097/AJP.0000000000001196.
- ACOG Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery. Obstet Gynecol. 2018 Sep;132(3):e120-e130. doi: 10.1097/AOG.0000000000002818.
- Huang Y, Lu Y, Wang J, Lu Q, Bao HF, Liu L, Dong CS. Effect of Pericapsular Nerve Group Block with Different Concentrations and Volumes of Ropivacaine on Functional Recovery in Total Hip Arthroplasty: A Randomized, Observer-Masked, Controlled Trial. J Pain Res. 2024 Feb 14;17:677-685. doi: 10.2147/JPR.S445000. eCollection 2024.
- Wegmann T. [Detection and treatment of rabies in humans]. Schweiz Med Wochenschr. 1966 Jun 11;96(23):743-6. No abstract available. German.
- Hin PC. Laparoscopic-assisted gastrostomy in 26 patients: indications and outcome at 2 years. J Laparoendosc Surg. 1996 Feb;6(1):25-8. doi: 10.1089/lps.1996.6.25.
- Slopnick EA, Sears SB, Chapman GC, Sheyn DD, Abrams MK, Roberts KM, Pollard R, Mangel J. Pudendal Nerve Block Analgesia at the Time of Vaginal Surgery: A Randomized, Double-Blinded, Sham-Controlled Trial. Urogynecology (Phila). 2023 Oct 1;29(10):827-835. doi: 10.1097/SPV.0000000000001351. Epub 2023 Apr 4.
- Goidescu OC, Dogaru IA, Badea TG, Enyedi M, Enciu O, Gheoca Mutu DE, Filipoiu FM. The distribution of the inferior hypogastric plexus in female pelvis. J Med Life. 2022 Jun;15(6):784-791. doi: 10.25122/jml-2022-0145.
- Hartmann F. [75th Anniversary of professor Dr. Rudolf Schoen]. Med Klin. 1967 Feb 24;62(8):314-6. No abstract available. German.
- Aurore V, Rothlisberger R, Boemke N, Hlushchuk R, Bangerter H, Bergmann M, Imboden S, Mueller MD, Eppler E, Djonov V. Anatomy of the female pelvic nerves: a macroscopic study of the hypogastric plexus and their relations and variations. J Anat. 2020 Sep;237(3):487-494. doi: 10.1111/joa.13206. Epub 2020 May 19.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2026-1073
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
To avoid breeches of privacy and confidentiality
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .